RecruitingPhase 2NCT06973668
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
Studying Macrophagic myofasciitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Uday Popat, MBA,MDM.D. Anderson Cancer Center
- Intervention
- Mycophenolate Mofetil(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 65-75 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06973668 on ClinicalTrials.gov